These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 17113893

  • 1. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC, Chih SY, Chen MC.
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [Abstract] [Full Text] [Related]

  • 3. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A, Wyndaele JJ, Sieber P.
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [Abstract] [Full Text] [Related]

  • 5. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F, Vsetica J, Abadías M, Pavlík I, Schraml P, Brod'ák M, Villoria J, Sust M, E-4018/CL50 Study Group.
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [Abstract] [Full Text] [Related]

  • 6. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J, Tamsulosin Study Group.
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ.
    Neurourol Urodyn; 2009 Oct; 28(1):47-51. PubMed ID: 19089890
    [Abstract] [Full Text] [Related]

  • 8. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, Dahl NV.
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Japanese Solifenacin Study Group.
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [Abstract] [Full Text] [Related]

  • 10. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA.
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [Abstract] [Full Text] [Related]

  • 11. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
    Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S.
    Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
    [Abstract] [Full Text] [Related]

  • 12. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [Abstract] [Full Text] [Related]

  • 13. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 14. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M, Weiss H, Seidman L.
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [Abstract] [Full Text] [Related]

  • 15. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F.
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [Abstract] [Full Text] [Related]

  • 16. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 17. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J, SUNRISE Study Group.
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [Abstract] [Full Text] [Related]

  • 18. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
    Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, Colli J, Vaughan CP, Redden DT.
    J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152
    [Abstract] [Full Text] [Related]

  • 19. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, 037 Study Group.
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [Abstract] [Full Text] [Related]

  • 20. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD, Lucente V, Vapnek J, Smith N.
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.